Collections
This class action lawsuit, brought on behalf of consumers and third-party payers in Illinois, Missouri, and New York, alleged that Forest Pharmaceuticals engaged in a program of deceptive conduct, carefully crafted around a nuanced regulatory scheme. Using a misleading drug label, the 'endorsements' of paid opinion leaders, gerrymandered clinical trials and a large group of specially trained sales personnel, Forest misled consumers and the medical community about Celexa’s and Lexapro’s efficacy in treating pediatric depression.
Report: How Forest Misled the FDA, USAO, and the Public about the Results of Celexa Study MD-18, January 2018
